NCT02811224Active, not recruiting
Ovarian Cancer Hemoscope Trial
Source: ClinicalTrials.gov · Last updated 16 Jan 2025
Brief summary (registry, in English)
This is a prospective, gold standard observational trial designed to enroll consecutive, consenting ovarian cancer patients for the purpose of determining sensitivity of an assay that detects circulating tumor DNA. This observational pilot trial will also be used to examine the genetic variants/mutations present in the tumor tissue DNA.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 21 Jun 2016
- Start date
- 1 May 2016
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Scripps Translational Science Institute
- Diseases
- Ovarian cancer
- NCT number
- NCT02811224
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 May 2016 to the primary completion date, 30 Jun 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Radiation therapy before surgical treatment
- Bone marrow transplant
- Chemotherapy before surgical treatment
- Invasive procedure resulting in damage to tissue (e.g., surgery, biopsy, thermal ablation) in the 7 days prior to baseline (pre-surgical) blood collection
Other illness
- Previous cancer diagnosis (all)
Who the study is looking for
- Case Group
- Patients with ovarian cancer undergoing surgery (all stages)
- Over 18 years old
- Control Group
- Patients with a benign gynecological condition undergoing surgery
- Over 18 years old
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.